Estados Unidos - inglês - NLM (National Library of Medicine)

apotex corporation - cefoxitin sodium (unii: q68050h03t) (cefoxitin - unii:6oev9dx57y) - many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to cefoxitin. similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin g) respond to treatment with cefoxitin. many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with cefoxitin. cefoxitin for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) lower respiratory tract infections , including pneumonia and lung abscess, caused by streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., enterococcus faecalis [formerly streptococcus faecalis ]), staphylococcus aureus (including penicillinase-producing strains), escherichia coli, klebsiella species, haemophilus influenzae, and bacteroides species. (2) urinary tract infections caused by

Estados Unidos - inglês - NLM (National Library of Medicine)

rebel distributors corp - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. warfarin sodium tablets are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. warfarin sodium tablets are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater than the potential clinical benefits of anticoagulation, such as: warfarin sodium tablets are contraindicated in women who are or may become pregnant because the drug passes through the placental barrier and may cause fatal hemorrhage to the fetus in utero. furthermore, there have been reports of birth malformations in children born to mothers who

Panamá - inglês - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

north china pharmaceutical co. ltd - cefoxitina sÓdica - cefoxitina sÓdica....1.0 g

Panamá - inglês - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios richet s.a. - cefoxitina (cefoxitina sÓdica) - cefoxitina (cefoxitina sÓdica)....1.0 g

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - 2/0.25 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - 4/0.5 gram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

viatris limited - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

viatris limited - piperacillin sodium; tazobactam (as sodium salt) - powder for solution for infusion - combinations of penicillins, incl. beta-lactamase inhibitors; piperacillin and enzyme inhibitor

Estados Unidos - inglês - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 500 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cilastatin sodium 530.7mg equivalent to 500 mg cilastatin; imipenem monohydrate 530.1mg equivalent to 500 mg imipenem - powder for injection - 500mg/500mg - active: cilastatin sodium 530.7mg equivalent to 500 mg cilastatin imipenem monohydrate 530.1mg equivalent to 500 mg imipenem excipient: sodium bicarbonate - indicated for the treatment of the following infections due to susceptible organisms: · intra-abdominal infections · lower respiratory tract infections · gynaecological infections · septicaemia · genitourinary tract infections · bone and joint infections · skin and soft tissue infections · endocarditis indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. the majority of these mixed infections are associated with contamination by faecal flora or flora originating from the vagina, skin and mouth. in these mixed infections, bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, ephalosporins and penicillins. however, bacteroides fragilis is usually susceptible to imipenem and cilastatin combination. imipenem and cilastatin combination has demonstrated efficacy against many infections caused by aerobic and anaerobic gram-positive and gram-negative bacteria resistant to the cephalosporins, including cefazolin, cefoperazone, cephalothin, cefoxitin, cefotaxime, moxalactam, cefamandole, ceftazidime and ceftriaxone. similarly, many infections caused by organisms resistant to aminoglycosides (gentamicin, amikacin, tobramycin) and/or penicillins (ampicillin, carbenicillin, penicillin-g, ticarcillin, piperacillin, azlocillin, mezlocillin) responded to treatment imipenem and cilastatin. imipenem+cilastatin rbx is not indicated for the treatment of meningitis.